Scholarlink

<p>This study evaluated the therapeutic effects of black garlic polysaccharides (BGPs) on slow transit constipation (STC)-like dysfunction in mice and compared their response profile with that of mosapride. A mouse model of STC-like dysfunction was established using a composite induction protocol. Mice were treated with mosapride or different doses of BGPs for 7 days. Body weight, intestinal transit rate, colonic water content, and fecal water content were evaluated. Colonic histopathology was assessed by hematoxylin and eosin (H&amp;E) staining. c-Kit immunohistochemistry was examined in the myenteric region of the colonic muscularis, and gut microbiota composition was profiled by 16 S rRNA sequencing. Both BGPs and mosapride improved key constipation-related functional outcomes, including intestinal motility and hydration-related indices. BGPs were also associated with improved colonic histopathology, increased c-Kit immunostaining and treatment-associated changes in the genus Colidextribacter, which was reduced in the Model group. These effects were more evident in the BGP-M and BGP-H groups. BGPs alleviated constipation-like dysfunction in mice and showed a response profile distinct from that of mosapride. Treatment with BGPs was also associated with histopathological, c-Kit-related, and microbiota-related changes. These findings support further investigation of BGPs as a food-derived candidate for constipation management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A food-derived intervention: black garlic polysaccharides alleviate slow transit constipation with multifaceted improvements in gastrointestinal function and microbiota

  • 期刊论文

  • 发表日期：

    2026年7月7日

查看全文
  • Zhu Ruiqing,
  • Guan Mengyao,
  • Li Kun,
  • Chen Yabo,
  • Chen Xiaojie,
  • Jiang Yiping,
  • Xia Tianshuang,
  • Xin Hailiang

摘要

This study evaluated the therapeutic effects of black garlic polysaccharides (BGPs) on slow transit constipation (STC)-like dysfunction in mice and compared their response profile with that of mosapride. A mouse model of STC-like dysfunction was established using a composite induction protocol. Mice were treated with mosapride or different doses of BGPs for 7 days. Body weight, intestinal transit rate, colonic water content, and fecal water content were evaluated. Colonic histopathology was assessed by hematoxylin and eosin (H&E) staining. c-Kit immunohistochemistry was examined in the myenteric region of the colonic muscularis, and gut microbiota composition was profiled by 16 S rRNA sequencing. Both BGPs and mosapride improved key constipation-related functional outcomes, including intestinal motility and hydration-related indices. BGPs were also associated with improved colonic histopathology, increased c-Kit immunostaining and treatment-associated changes in the genus Colidextribacter, which was reduced in the Model group. These effects were more evident in the BGP-M and BGP-H groups. BGPs alleviated constipation-like dysfunction in mice and showed a response profile distinct from that of mosapride. Treatment with BGPs was also associated with histopathological, c-Kit-related, and microbiota-related changes. These findings support further investigation of BGPs as a food-derived candidate for constipation management.